{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:50:14Z","timestamp":1778903414370,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T00:00:00Z","timestamp":1441152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s12032-015-0684-x","type":"journal-article","created":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T15:27:39Z","timestamp":1441121259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma"],"prefix":"10.1007","volume":"32","author":[{"given":"Jianhua","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinguang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,2]]},"reference":[{"key":"684_CR1","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/bmj.318.7192.1209","volume":"318","author":"DG Altman","year":"1999","unstructured":"Altman DG, Bland JM. Statistics notes. Treatment allocation in controlled trials: why randomise? BMJ. 1999;318:1209.","journal-title":"BMJ"},{"key":"684_CR2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","volume":"57","author":"J Bruix","year":"2012","unstructured":"Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821\u20139.","journal-title":"J Hepatol"},{"key":"684_CR3","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208\u201336.","journal-title":"Hepatology"},{"key":"684_CR4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF01978799","volume":"11","author":"F Capasso","year":"1981","unstructured":"Capasso F. Some pharmacological properties of tiopronin. Agents Actions. 1981;11:741\u20135.","journal-title":"Agents Actions"},{"key":"684_CR5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/BF00196122","volume":"46","author":"MS Carlsson","year":"1994","unstructured":"Carlsson MS, Denneberg T, Emanuelsson BM, Kagedal B, Lindgren S. The pharmacokinetics of tiopronin as such is unknown. Eur J Clin Pharmacol. 1994;46:576\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"684_CR6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12094-008-0256-5","volume":"10","author":"I Castro Beza","year":"2008","unstructured":"Castro Beza I, Sanchez Ruiz J, Peracaula Espino FJ, Villanego Beltran MI. Drug-related hepatotoxicity and hepatic failure following combined androgen blockade. Clin Transl Oncol. 2008;10:591\u20132.","journal-title":"Clin Transl Oncol"},{"key":"684_CR7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"684_CR8","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1128\/AAC.01543-06","volume":"51","author":"BI Hernandez-Santiago","year":"2007","unstructured":"Hernandez-Santiago BI, Mathew JS, Rapp KL, Grier JP, Schinazi RF. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. Antimicrob Agents Chemother. 2007;51:2130\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"684_CR9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/00313028109059059","volume":"13","author":"J Ho","year":"1981","unstructured":"Ho J, Wu PC, Kung TM. An autopsy study of hepatocellular carcinoma in Hong Kong. Pathology. 1981;13:409\u201316.","journal-title":"Pathology"},{"key":"684_CR10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/1636.17908","volume":"100","author":"XP Li","year":"2014","unstructured":"Li XP, Wen F, Yang W, Deng YB, Li M, Zhang PF, Tang RL, Li Q, Wei YQ. The role of tiopronin for the prevention of chemotherapy-related liver toxicity in advanced colorectal cancer patients treated with mFOLFOX7: a prospective analysis. Tumori. 2014;100:446\u201351.","journal-title":"Tumori"},{"key":"684_CR11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582\u201392.","journal-title":"Lancet"},{"key":"684_CR12","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","volume":"108","author":"E Lierman","year":"2006","unstructured":"Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood. 2006;108:1374\u20136.","journal-title":"Blood"},{"key":"684_CR13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/jgh.12898","volume":"30","author":"S Lim","year":"2015","unstructured":"Lim S, Han J, Kim GM, Han KH, Choi HJ. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol. 2015;30:1024\u201331.","journal-title":"J Gastroenterol Hepatol"},{"key":"684_CR14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"684_CR15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/oxfordjournals.aje.a114681","volume":"126","author":"AS Lok","year":"1987","unstructured":"Lok AS, Lai CL, Wu PC, Wong VC, Yeoh EK, Lin HJ. Hepatitis B virus infection in Chinese families in Hong Kong. Am J Epidemiol. 1987;126:492\u20139.","journal-title":"Am J Epidemiol"},{"key":"684_CR16","doi-asserted-by":"crossref","first-page":"29230","DOI":"10.1074\/jbc.M703461200","volume":"282","author":"I Plaza-Menacho","year":"2007","unstructured":"Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007;282:29230\u201340.","journal-title":"J Biol Chem"},{"key":"684_CR17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5\u201329.","journal-title":"CA Cancer J Clin"},{"key":"684_CR18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"684_CR19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00534-011-0489-z","volume":"19","author":"Y Urata","year":"2012","unstructured":"Urata Y, Kubo S, Takemura S, Uenishi T, Kodai S, Shinkawa H, Sakae M, Kaneda K, Ohata K, Nozawa A, Suehiro S. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19:685\u201396.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"684_CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00520-010-1078-4","volume":"20","author":"B Vincenzi","year":"2012","unstructured":"Vincenzi B, Daniele S, Frezza AM, Berti P, Vespasiani U, Picardi A, Tonini G. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer. 2012;20:135\u20139.","journal-title":"Support Care Cancer"},{"key":"684_CR21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/aps.2012.19","volume":"33","author":"JQ Wang","year":"2012","unstructured":"Wang JQ, Zou YH, Huang C, Lu C, Zhang L, Jin Y, Lu XW, Liu LP, Li J. Protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats. Acta Pharmacol Sin. 2012;33:791\u20137.","journal-title":"Acta Pharmacol Sin"},{"key":"684_CR22","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/MCG.0b013e31818ddfc6","volume":"43","author":"MA Worns","year":"2009","unstructured":"Worns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Duber C, Otto G, Galle PR. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009;43:489\u201395.","journal-title":"J Clin Gastroenterol"},{"key":"684_CR23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/jgh.12910","volume":"30","author":"L Xu","year":"2015","unstructured":"Xu L, Gao H, Huang J, Wang H, Zhou Z, Zhang Y, Li S, Chen M. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol. 2015;30:1032\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"684_CR24","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/liv.12805","volume":"35","author":"Y Yang","year":"2015","unstructured":"Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, Xia F, Bi F, Li Q. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int. 2015;35(9):2147\u201354.","journal-title":"Liver Int"},{"key":"684_CR25","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1158\/1078-0432.CCR-12-1967","volume":"18","author":"EI Zimmerman","year":"2012","unstructured":"Zimmerman EI, Roberts JL, Li L, Finkelstein D, Gibson A, Chaudhry AS, Schuetz EG, Rubnitz JE, Inaba H, Baker SD. Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012;18:5788\u201395.","journal-title":"Clin Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0684-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-015-0684-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-015-0684-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T02:17:00Z","timestamp":1567131420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-015-0684-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,2]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1007\/s12032-015-0684-x","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,2]]},"article-number":"238"}}